Bioheart, Inc. Expands Clinical Trials Of Adult Myogenic Stem Cell Treatment For Heart Attack And Advanced Heart Failure Patients

Source: Bioheart, Inc.
Date: November 17, 2006

Summary:

Bioheart, Inc., a biotechnology company focused on the development of innovative cell therapies designed to repair areas of damaged muscle tissue in a patient's heart and improve cardiac function, is expanding its United States and European clinical trials of its MyoCell(TM) adult myogenic (muscle) stem cell composition and MyoCath(R) needle-injection catheter product candidates.